Background. The limited access to virological monitoring in developing countries is a major
weakness of the current antiretroviral treatment (ART) strategy in these settings. We …

Objective This study aims to describe the virological, immunological and clinical efficacy of
protease inhibitor (PI)-based second-line antiretroviral therapy (ART) in rural South Africa …

BACKGROUND: Emergence of HIV-1 drug resistance may limit the sustained benefits of
antiretroviral therapy (ART) in settings with limited laboratory monitoring and drug options …

Objectives To assess second‐line antiretroviral therapy (ART) virological failure and HIV
drug resistance‐associated mutations (RAMs), in support of third‐line regimen planning in …

Objective: In resource-limited countries, antiretroviral therapy (ART) has been scaled up, but
individual monitoring is still suboptimal. Here, we studied whether or not ART had an impact …

Protease inhibitor (PI)-based antiretroviral therapy (ART) can effectively suppress HIV-2
plasma load and increase CD4 counts; however, not all PIs are equally active against HIV-2 …

Objectives We describe the outcomes of second-line drug resistance profiles and predict the
efficacy of drugs for third-line therapy in patients monitored without the benefit of plasma HIV …

We performed a countrywide assessment of HIV drug resistance among 123 patients with
virological failure on second-line antiretroviral therapy (ART) in Kenya. The percentage of …

Currently the prevalence of HIV‐1 infection in Cameroon is 5.1%, CRF02_AG subtype is
responsible for about 50% of infections. Since an HIV‐1 drug resistance test is not yet …

Non‐B HIV subtypes have been estimated to account for 88% of HIV infections in the world.
These subtypes are particularly relevant in view of the availability of antiretroviral (ARV) …